First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

This study aimed to identify a recommended phase II dose and evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary clinical activity of JNJ‐63709178, a CD123/CD3 dual‐targeting antibody, in patients with relapsed or refractory acute myeloid leukemia. Intravenous (i.v....

Descripción completa

Detalles Bibliográficos
Autores principales: Boyiadzis, Michael, Desai, Pinkal, Daskalakis, Nikki, Donnellan, William, Ferrante, Lucille, Goldberg, Jenna D., Grunwald, Michael R., Guttke, Christina, Li, Xiang, Perez‐Simon, Jose Antonio, Salamero, Olga, Tucker, Trevor, Xu, Xiaoying, Yang, Jay, Pemmaraju, Naveen, Alonso‐Dominguez, Juan Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014690/
https://www.ncbi.nlm.nih.gov/pubmed/36564917
http://dx.doi.org/10.1111/cts.13467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014690/
https://www.ncbi.nlm.nih.gov/pubmed/36564917
http://dx.doi.org/10.1111/cts.13467

Ejemplares similares